Zinc aspartate

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Human trial1

Outcomes

SLC39A8

upin humans1

1 study

Zinc aspartate increases SLC39A8 in humans.
“in participants taking PPIs, this increase reached statistical significance.”
Human trialzinc-deficient elderly participants taking PPIsapproximately 7 days
Zinc Supplementation Partially Reconstitutes Impaired Interferon-γ Production in the Elderly
International journal of molecular sciences20 Jan 2026

Latest

1 in 12 months

International Journal of Molecular Sciences28 Jan

Zinc Supplementation Partially Reconstitutes Impaired Interferon-γ Production in the Elderly

Non-randomised trial in peopleZinc

Paper

Zinc aspartate

Outcomes

Latest

Zinc Supplementation Partially Reconstitutes Impaired Interferon-γ Production in the Elderly

Related